To address the relationship of TGFβ stimulated SMAD4-dependent target genes and clinical outcome of ovarian cancer patients, we examined the 307 target genes identified in A2780 cells in this study, which were not identified in previous studies of normal cells, in two different clinical ovarian cancer cohort studies that had reported survival data [36], [37]. This evidence concerns the gene SMAD4 and ovarian cancer.